334 related articles for article (PubMed ID: 26192479)
1. Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier.
Di Gioia S; Trapani A; Castellani S; Carbone A; Belgiovine G; Craparo EF; Puglisi G; Cavallaro G; Trapani G; Conese M
Pulm Pharmacol Ther; 2015 Oct; 34():8-24. PubMed ID: 26192479
[TBL] [Abstract][Full Text] [Related]
2. Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems.
Rezaee M; Oskuee RK; Nassirli H; Malaekeh-Nikouei B
J Control Release; 2016 Aug; 236():1-14. PubMed ID: 27317365
[TBL] [Abstract][Full Text] [Related]
3. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
4. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier.
Suk JS; Kim AJ; Trehan K; Schneider CS; Cebotaru L; Woodward OM; Boylan NJ; Boyle MP; Lai SK; Guggino WB; Hanes J
J Control Release; 2014 Mar; 178():8-17. PubMed ID: 24440664
[TBL] [Abstract][Full Text] [Related]
5. Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?
Conte G; Costabile G; Baldassi D; Rondelli V; Bassi R; Colombo D; Linardos G; Fiscarelli EV; Sorrentino R; Miro A; Quaglia F; Brocca P; d'Angelo I; Merkel OM; Ungaro F
ACS Appl Mater Interfaces; 2022 Feb; 14(6):7565-7578. PubMed ID: 35107987
[TBL] [Abstract][Full Text] [Related]
6. PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy.
Osman G; Rodriguez J; Chan SY; Chisholm J; Duncan G; Kim N; Tatler AL; Shakesheff KM; Hanes J; Suk JS; Dixon JE
J Control Release; 2018 Sep; 285():35-45. PubMed ID: 30004000
[TBL] [Abstract][Full Text] [Related]
7. Pegylated Polyaspartamide-Polylactide-Based Nanoparticles Penetrating Cystic Fibrosis Artificial Mucus.
Craparo EF; Porsio B; Sardo C; Giammona G; Cavallaro G
Biomacromolecules; 2016 Mar; 17(3):767-77. PubMed ID: 26866983
[TBL] [Abstract][Full Text] [Related]
8. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
9. N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles.
Suk JS; Boylan NJ; Trehan K; Tang BC; Schneider CS; Lin JM; Boyle MP; Zeitlin PL; Lai SK; Cooper MJ; Hanes J
Mol Ther; 2011 Nov; 19(11):1981-9. PubMed ID: 21829177
[TBL] [Abstract][Full Text] [Related]
10. The Mucus Barrier to Inhaled Gene Therapy.
Duncan GA; Jung J; Hanes J; Suk JS
Mol Ther; 2016 Dec; 24(12):2043-2053. PubMed ID: 27646604
[TBL] [Abstract][Full Text] [Related]
11. Highly mucus permeating and zeta potential changing self-emulsifying drug delivery systems: A potent gene delivery model for causal treatment of cystic fibrosis.
Griesser J; Hetényi G; Federer C; Steinbring C; Ellemunter H; Niedermayr K; Bernkop-Schnürch A
Int J Pharm; 2019 Feb; 557():124-134. PubMed ID: 30594687
[TBL] [Abstract][Full Text] [Related]
12. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics.
Broughton-Head VJ; Smith JR; Shur J; Shute JK
Pulm Pharmacol Ther; 2007; 20(6):708-17. PubMed ID: 17055310
[TBL] [Abstract][Full Text] [Related]
13. Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.
McLachlan G; Davidson H; Holder E; Davies LA; Pringle IA; Sumner-Jones SG; Baker A; Tennant P; Gordon C; Vrettou C; Blundell R; Hyndman L; Stevenson B; Wilson A; Doherty A; Shaw DJ; Coles RL; Painter H; Cheng SH; Scheule RK; Davies JC; Innes JA; Hyde SC; Griesenbach U; Alton EW; Boyd AC; Porteous DJ; Gill DR; Collie DD
Gene Ther; 2011 Oct; 18(10):996-1005. PubMed ID: 21512505
[TBL] [Abstract][Full Text] [Related]
14. Brain-targeting delivery for RNAi neuroprotection against cerebral ischemia reperfusion injury.
An S; Kuang Y; Shen T; Li J; Ma H; Guo Y; He X; Jiang C
Biomaterials; 2013 Nov; 34(35):8949-59. PubMed ID: 23968852
[TBL] [Abstract][Full Text] [Related]
15. Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy.
Griesenbach U; Alton EW;
Adv Drug Deliv Rev; 2009 Feb; 61(2):128-39. PubMed ID: 19138713
[TBL] [Abstract][Full Text] [Related]
16. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy.
Mastorakos P; da Silva AL; Chisholm J; Song E; Choi WK; Boyle MP; Morales MM; Hanes J; Suk JS
Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8720-5. PubMed ID: 26124127
[TBL] [Abstract][Full Text] [Related]
17. Physical and biological barriers to viral vector-mediated delivery of genes to the airway epithelium.
Pickles RJ
Proc Am Thorac Soc; 2004; 1(4):302-8. PubMed ID: 16113450
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for cystic fibrosis lung disease: current status and future perspectives.
Rosenecker J; Huth S; Rudolph C
Curr Opin Mol Ther; 2006 Oct; 8(5):439-45. PubMed ID: 17078386
[TBL] [Abstract][Full Text] [Related]
19. From Genesis to Revelation: The Role of Inflammatory Mediators in Chronic Respiratory Diseases and their Control by Nucleic Acid-based Drugs.
Gioia SD; Sardo C; Castellani S; Porsio B; Belgiovine G; Carbone A; Giammona G; Cavallaro G; Conese M
Curr Drug Deliv; 2017; 14(2):253-271. PubMed ID: 27557670
[TBL] [Abstract][Full Text] [Related]
20. Surface Coating Approach to Overcome Mucosal Entrapment of DNA Nanoparticles for Oral Gene Delivery of Glucagon-like Peptide 1.
Nie T; He Z; Zhou Y; Zhu J; Chen K; Liu L; Leong KW; Mao HQ; Chen Y
ACS Appl Mater Interfaces; 2019 Aug; 11(33):29593-29603. PubMed ID: 31348859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
